In endometrial cancer, they found that expression of MRPS18B was positively correlated with free E2F1 in 84 patient samples, with expression of both proteins significantly increased compared to normal and hyperplasia samples [28] [E2F1 is a potential driver of metastasis and is highly expressed in late-stage endometrial tumours [37]]. Additionally, morphological changes in endometrial cancer cells expressing high levels of MRPS18B suggested progression of EMT, which was not observed in cells with lower MRPS18B expression [28]. This evidence concerns the gene E2F1 and endometrial cancer.